Skip to main content

Table 2 Subgroup analysis for overall survival in cancer patients with higher MDSCs

From: Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis

Subgroup analysis

No. of studies

No. of patients

Pooled HR(95%CI)

Heterogeneity

Fixed

Random

I2

p-value

Region

 Eastern

13

936

2.47 (1.95,3.12)

2.47 (1.95,3.12)

0%

0.892

 Western

6

521

1.35 (1.18,1.54)

2.37 (1.41,3.97)

75.8%

0.001

Sample size

 <50

7

225

2.67 (1.85,3.84)

2.67 (1.85,3.84)

0%

0.786

 ≥50, < 100

9

680

2.26 (1.78,2.88)

2.37 (1.78,3.14)

18.9%

0.275

 ≥100

3

552

1.27 (1.11,1.46)

2.04 (0.95,4.37)

74.5%

0.020

Cancer types

 GI cancers

8

631

1.36 (1.20,1.55)

1.92 (1.36,2.72)

54.2%

0.033

 HCC

3

367

2.41 (1.53,3.82)

2.41 (1.53,3.82)

0%

0.965

 NKT

2

64

6.02 (1.70,21.28)

6.02 (1.70,21.28)

0%

0.670

 Melanoma

3

214

2.24(1.50,3.35)

3.87 (1.24,12.04)

73.9%

0.022

 Other types

3

181

3.07 (1.91,4.92)

3.07 (1.91,4.92)

0%

0.912

Subtypes

 Total-MDSCs

10

765

1.40 (1.23,1.60)

2.53 (1.63,3.94)

68.4%

0.001

 PMN-MDSCs

5

487

2.32 (1.73,3.13)

2.32 (1.73,3.13)

0%

0.912

 Mo-MDSCs

4

205

2.08 (1.40,3.11)

2.95 (1.34,6.51)

45.9%

0.136

Cut-off value

 <10

14

1024

1.46 (1.29,1.66)

2.56 (1.79,3.67)

64.3%

0.001

 ≥10

5

433

2.23 (1.67,2.98)

2.23 (1.67,2.98)

0%

0.527

NOS score

 <7

10

901

2.59 (2.02,3.31)

2.59 (2.02,3.31)

0%

0.770

 ≥7

9

556

2.17 (1.45,3.25)

1.36 (1.19,1.55)

60.5%

0.009